752 related articles for article (PubMed ID: 36192086)
21. Tumor cell senescence-induced macrophage CD73 expression is a critical metabolic immune checkpoint in the aging tumor microenvironment.
Deng Y; Chen Q; Yang X; Sun Y; Zhang B; Wei W; Deng S; Meng J; Hu Y; Wang Y; Zhang Z; Wen L; Huang F; Wan C; Yang K
Theranostics; 2024; 14(3):1224-1240. PubMed ID: 38323313
[No Abstract] [Full Text] [Related]
22. Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence.
Ye J; Ma C; Hsueh EC; Eickhoff CS; Zhang Y; Varvares MA; Hoft DF; Peng G
J Immunol; 2013 Mar; 190(5):2403-14. PubMed ID: 23355732
[TBL] [Abstract][Full Text] [Related]
23. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
24. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
25. Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.
Scherrer D; Barrett N; Teyton L; Pearce T; Nitcheu J; Pouletty P; Santo J; Ehrlich HJ
Mol Cancer Ther; 2022 Dec; 21(12):1788-1797. PubMed ID: 36198025
[TBL] [Abstract][Full Text] [Related]
26. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity.
Punt S; Malu S; McKenzie JA; Manrique SZ; Doorduijn EM; Mbofung RM; Williams L; Silverman DA; Ashkin EL; Dominguez AL; Wang Z; Chen JQ; Maiti SN; Tieu TN; Liu C; Xu C; Forget MA; Haymaker C; Khalili JS; Satani N; Muller F; Cooper LJN; Overwijk WW; Amaria RN; Bernatchez C; Heffernan TP; Peng W; Roszik J; Hwu P
Cancer Immunol Immunother; 2021 Apr; 70(4):1101-1113. PubMed ID: 33123754
[TBL] [Abstract][Full Text] [Related]
27. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
28. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
29. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
[TBL] [Abstract][Full Text] [Related]
30. Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling.
Brown MC; Mosaheb MM; Mohme M; McKay ZP; Holl EK; Kastan JP; Yang Y; Beasley GM; Hwang ES; Ashley DM; Bigner DD; Nair SK; Gromeier M
Nat Commun; 2021 Mar; 12(1):1858. PubMed ID: 33767151
[TBL] [Abstract][Full Text] [Related]
31. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
32. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
33. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
34. Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8
Li A; Chang Y; Song NJ; Wu X; Chung D; Riesenberg BP; Velegraki M; Giuliani GD; Das K; Okimoto T; Kwon H; Chakravarthy KB; Bolyard C; Wang Y; He K; Gatti-Mays M; Das J; Yang Y; Gewirth DT; Ma Q; Carbone D; Li Z
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096533
[TBL] [Abstract][Full Text] [Related]
35. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
36. Genes associated with cellular senescence favor melanoma prognosis by stimulating immune responses in tumor microenvironment.
Liang X; Lin X; Lin Z; Lin W; Peng Z; Wei S
Comput Biol Med; 2023 May; 158():106850. PubMed ID: 37031510
[TBL] [Abstract][Full Text] [Related]
37. Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition.
Liu X; Mo W; Ye J; Li L; Zhang Y; Hsueh EC; Hoft DF; Peng G
Nat Commun; 2018 Jan; 9(1):249. PubMed ID: 29339767
[TBL] [Abstract][Full Text] [Related]
38. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy.
Liu HY; Pedros C; Kong KF; Canonigo-Balancio AJ; Xue W; Altman A
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34588224
[TBL] [Abstract][Full Text] [Related]
39. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
[TBL] [Abstract][Full Text] [Related]
40. Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR.
Liu X; Yin M; Dong J; Mao G; Min W; Kuang Z; Yang P; Liu L; Zhang N; Deng H
Acta Pharm Sin B; 2021 Oct; 11(10):3134-3149. PubMed ID: 34745852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]